ANI Pharmaceuticals (ANIP) Competitors

ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Does the media prefer ADMA or ANIP?

In the previous week, ANI Pharmaceuticals had 12 more articles in the media than ADMA Biologics. MarketBeat recorded 15 mentions for ANI Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.48 beat ANI Pharmaceuticals' score of 1.12 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ADMA or ANIP?

ADMA Biologics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Which has higher valuation and earnings, ADMA or ANIP?

ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$426.45M	9.01	$197.67M	$0.86	18.73
ANI Pharmaceuticals	$747.40M	2.87	-$18.52M	-$0.77	-128.22

Is ADMA or ANIP more profitable?

ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	44.06%	41.01%	28.47%
ANI Pharmaceuticals	-1.37%	25.03%	8.00%

Do analysts prefer ADMA or ANIP?

ADMA Biologics presently has a consensus price target of $27.67, indicating a potential upside of 71.74%. ANI Pharmaceuticals has a consensus price target of $88.25, indicating a potential downside of 10.61%. Given ADMA Biologics' stronger consensus rating and higher probable upside, research analysts clearly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.10

Do insiders and institutionals believe in ADMA or ANIP?

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ADMA Biologics beats ANI Pharmaceuticals on 10 of the 17 factors compared between the two stocks.